 Fate Therapeutics Inc NASDAQ: FATE showcased interim Phase 1 data from its FT596 program for patients with relapsed refractory B-cell lymphoma BCL at the American Society of Hematology ASH Annual Meeting and Exposition. In the second, third, and fourth dose cohorts of monotherapy and combination arms comprising 26 patients, 18 patients 69 achieved an objective response, including 12 patients 46 that achieved a complete response, on Day 29 following a single dose of FT596. 